Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant for Conversion of Atrial Fibrillation
NCT01174160Phase 3Completed
- Sponsor
- ADVANZ PHARMA
- Start
- Aug 2010
- Primary completion
- Sep 2012
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vernakalant in Atrial fibrillation (AFib), sponsored by ADVANZ PHARMA. Started Aug 2010; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01174160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01174160.